The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population
Open accessAbstract
Despite advances in graft-versus-host-disease (GVHD) treatment, it is estimated that overall survival (OS) at 2 years for hematopoietic cell transplantation (HCT) recipients who experience steroid-resistant GVHD is 10%. Among recent therapeutic approaches for GVHD treatment, mesenchymal stromal cells (MSCs) hold a key position. We describe a multicenter experience of 11 pediatric patients diagnosed with acute or chronic GVHD (aGVHD, cGVHD) treated for compassionate use with GMP-grade unrelated HLA-disparate donors' bone marrow-derived MSCs, expanded in platelet-lysate (PL)-containing medium. Eleven patients (aged 4-15 years) received intravenous (i.v.) MSCs for aGVHD or cGVHD, which was resistant to multiple lines of immunosuppression. The median dose was 1.2 x 10(6)/kg (range: 0.7-3.7 x 10(6)/kg). No acute side effects were observed, and no late side effects were reported at a median follow-up of 8 months (range: 4-18 months). Overall response was obtained in 71.4% of patients, with complete response in 23.8% of cases. None of our patients presented GVHD progression upon MSC administration, but 4 patients presented GVHD recurrence 2 to 5 months after infusion. Two patients developed chronic limited GVHD. This study underlines the safety of PL-expanded MSC use in children. MSC efficacy seems to be greater in aGVHD than in cGVHD, even after failure of multiple lines of immunosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Species Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated Immunosuppression
Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'huillie, A., Zhang, J., Lu, Y., Roberts, A. I., Ji, W., et al. (2009) · Stem Cells · doi:10.1002/stem.118 · Cited by 597
Cited by
Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation
Bernardo, M. E., & Fibbe, W. E. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.09.006 · Cited by 1,383
Clinical applications of mesenchymal stem cells
Wang, S., Qu, X., & Zhao, R. C. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-19 · Cited by 483
Clinical applications of mesenchymal stem cells
Kim, N., & Cho, S.-G. (2013) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2013.28.4.387 · Cited by 314
The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity
Zhou, Y., Yamamoto, Y., Xiao, Z., & Ochiya, T. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071025 · Cited by 303
Perico, N., Casiraghi, F., Introna, M., Gotti, E., Todeschini, M., Cavinato, R. A., Capelli, C., Rambaldi, A., Cassis, P., Rizzo, P., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04950610 · Cited by 297
Self-citationKuci, Z., Bonig, H., Kreyenberg, H., Bunos, M., Jauch, A., Janssen, J. W. G., kifi, M., Michel, K., Eising, B., Lucchini, G., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140368 · Cited by 118
Self-citationTWIST1 and TSG6 are coordinately regulated and function as potency biomarkers in human MSCs
Lee, R. H., Boregowda, S. V., Shigemoto-Kuroda, T., Bae, E., Haga, C. L., Abbery, C. A., Bayless, K. J., Haskell, A., Gregory, C. A., Ortiz, L. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi2387 · Cited by 16
Metadata
- Authors
- Lucchini, G., Introna, M., Dander, E., Rovelli, A., Balduzzi, A., Bonanomi, S., Salvadè, A., Capelli, C., Belotti, D., Gaipa, G., Perseghin, P., Vinci, P., Lanino, E., Chiusolo, P., Orofino, M. G., Marktel, S., Golay, J., Rambaldi, A., Biondi, A., D'Amico, G., & Biagi, E.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 16
- Issue
- 9
- Pages
- 1293-1301
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2114998726
- Cited by
- 186
- References
- 2
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.